title: An industry update: the latest developments in therapeutic delivery.
abstract: The present industry update covers the period 1-31 January 2017, with information sourced from company press releases, regulatory and patent agencies as well as the scientific literature. With a new year come new resolutions, annual operation plans but also reports and outlooks for the years(s) to come. A number of the latter have been published in January forecasting various spaces in drug delivery (Market and Research). Also a number of financing deals were closed being fresh into the year such as Ossianix and Ocular Therapeutix and contract manufacturers will show their offerings at the 2017 MD&M West Medtech event (Lubrizol, Trelleborg). The US FDA released some new (draft) guidelines for combination products to regulate standards and disputes in this increasingly important field. Recent advances in artificial pancreas technology demonstrates that while the age of nanotechnology and gene therapy (Bluebird Bio) has arrived, implantable, closed-loop delivery systems (Medtronic) are just to pass successfully the clinic and come in reach of patients.
authors.affiliation: Philips Clinical Research Board, Chief Technology Office, 3000 Minuteman Road, Andover, MA 01810, USA.
authors.forename: Oliver C
authors.initials: OC
authors.lastname: Steinbach
keywords: blood–brain barrier; combination products; devices; emerging technologies; inhaled; nasal; peptides; small molecular drugs; targeting-molecular